Abstract
The transcription factor nuclear factor κB (NF-κB) is activated and seems to promote oncogenesis in certain cancers. A major mechanism of NF-κB activation in cells involves cytoplasm-to-nucleus translocation of this transcription factor after hydrolysis of the cytoplasmic inhibitor inhibitory κB (IκB) by the 26S proteasome. Because selective proteasome inhibitors have been shown to block IκB degradation; consequently, NF-κB activation in a variety of cellular systems, proteasome inhibitors were proposed as potential therapeutic agents for the treatment of cancer. However, under certain conditions, IκB degradation and NF-κB activation are not mediated by the proteasome system. We investigated how proteasome inhibitors affected NF-κB activation in the intestinal epithelial cancer cell line HT-29, which has been documented to have an atypical NF-κB regulation. Treatment of cells with the selective proteasome inhibitors carbobenzoxy-l-leucyl-l-leucyl-l-norvalinal (MG-115), carbobenzoxy-l-leucyl-l-leucyl-l-leucinal (MG-132), or lactacystin induced NF-κB activation as indicated by both an increase in NF-κB DNA binding and transcriptional activity. This increase in NF-κB activation caused by proteasome inhibitors was accompanied by an increase in IκB kinase activation and a degradation of IκBα but not IκBβ. Furthermore, proteasome inhibitors induced the expression of NF-κB target genes. In summary, these results demonstrate a unique effect of proteasome inhibitors on the IκB–NF-κB systems in HT-29 cells, in which proteasome inhibitors activate rather than deactivate the NF-κB system. We conclude that the use of proteasome inhibitors to block NF-κB activation in cancer cells may not always be a viable approach.
- Received July 8, 2003.
- Accepted October 21, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|